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Over the past 15 to 20 years, lung cancer has become the mostprevalent form of malignancy in men and the second most com-mon in women. In addition, it has also become the leading causeof cancer death in both men and women. Unfortunately, thesestatistics are unlikely to change in the near future even though thenumber of smokers in the United States has significantly de-
creased to 20% to 25% of the population.
In the management of lung cancer, surgical resection offers some possibility for
cure, although most new patients are first seen when it is already too late to operate.
Indeed, 5-year survival figures are consistently in the range of 10% to 12% even if
they rise to 25% to 30% in those few individuals who can have complete resection
of their tumors. The disease can, however, be cured in up to 70% of cases if
surgically managed while still in its earliest stages (clinical stages Ia and Ib).
Because of these better survival figures, it is tempting to assume that with lung
cancer screening, tumors will be diagnosed at an earlier stage and cure rates will be
higher. This seems even more likely if one considers that lung cancer should easily
be identifiable on chest radiographs or by sputum cytology. In this context, it may
be worth noting that tumors smaller than 2 cm are not necessarily early-stage
neoplasms (up to 20% already have N2 status); on the other hand, some of these
tumors can be slow growing so that 5-year survivals may not be an accurate way of
reporting results.
The two methods traditionally used for early detection of lung cancer are
standard chest radiographs and sputum cytologic examination. Chest radiographs
can detect lung nodules of 0.8 to 1 cm in diameter, whereas sputum cytology will
be “positive” in 30% to 40% of endobronchial lesions. Both techniques are inex-
pensive and excellent for individual cases. Three randomized studies1-3 done in the
1970s and supported by research contracts from the National Institutes of Health
have shown, however, that the death rate from lung cancer was not significantly
different in patients who were actively screened than in patients who were not
(3.2/1000 patients vs 3.0/1000 patients in the Mayo lung project3). Even if some of
the methods used in those trials were criticized, their failure to show a significant
reduction in cancer death rates was and still is considered strong evidence against
screening. These techniques may also have some potential to be harmful through
false positive radiographs (0%-10%/year), false positive cytologic reports (0%-1%/
year), and chances of incorrect cancer diagnosis (0%-1%/year).4
More recently, these techniques have evolved to those of screening by low-dose
helical computed tomography (CT) and use of specific biomarkers for lung cancer.
The Early Lung Cancer Action Project (ELCAP)5 notably looked at the usefulness
of annual helical low-dose CT scanning in 1000 heavy smokers over the age of 60
years. Helical CT detected 233 individuals (23%) with noncalcified nodules, but in
only 27 (12%) were the nodules malignant. Of these 27 patients, 16 are included in
the current report by Altorki and associates,6 which suggests that CT scan can detect
lung cancer at an earlier stage than chest radiographs. This would appear obvious
since CT scanning is much more sensitive to detect small nodules than standard
radiographs. Whether these findings translate into actual improvements in lung
cancer death rates (the most important end point in cancer screening) is unknown,
not only because the number of patients in the CT group is small, but also because
no long-term follow-up is given for this cohort. One should also note that 91% of
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patients in the CT group had adenocarcinoma, a ratio that
does not reflect the true proportions of this tumor among all
histologic types of lung cancer.
As shown by the original data from ELCAP,5 one of the
drawbacks of screening with low-dose helical CT is the
number of detected nodules that are initially interpreted as
being nonmalignant. If one was to keep the same ratio as
reported by ELCAP, screening by CT would translate into
finding approximately 220,000 presumably nonmalignant
nodules in a screened population of 1,000,000. What will be
done with these patients will largely be left to the judgment
of individual physicians, although this judgment is likely to
be influenced by the patient’s anxiety or the physician’s fear
of being involved in legal actions if a malignant nodule is
diagnosed too late. These are some of the reasons why I
think that screening by CT should be reserved for very
high-risk patients such as those heavy smokers (or former
heavy smokers) with a personal or family history of any
type of malignancy or with occupational exposure to known
carcinogens. Indeed, the highest risk group for lung cancer
is the group of patients with prior lung cancer (2%-5%/
year). The problem of over diagnosis, that is, diagnosing a
lung cancer that is unlikely to become life-threatening, is a
nonissue because it has been repeatedly shown that most
untreated lung cancers are likely to progress and cause death
within 5 years of their diagnosis. In the three screening
programs previously mentioned,1-3 the 5-year survival of
patients with screen-detected lung cancer who did not un-
dergo surgery was below 10%.
Perhaps a more specific method of screening patients at
risk for lung cancer is through the use of biomarkers applied
to sputum specimens. In 1988, Tockman and associates7
reported on two monoclonal antibodies (703D4 and
624H12) that were identified as biomarkers of lung cancer.
When applied to the Johns Hopkins early lung cancer spec-
imens, these antibodies together showed a sensitivity of
91% and a specificity of 88% for the diagnosis of lung
cancer within 2 years. Since then, clinical trials to evaluate
these biomarkers have been designed with the hypothesis
that screening with immunostaining techniques will in-
crease the percentage of detected stage I lung cancers at
least 3-fold.8 It is of interest to note that sputum for cyto-
logic analysis is best obtained after saline aerosol induction
and that microscopic workstations have already been devel-
oped to extract positive immunostained cells. It may soon be
possible that chemo-preventive agents delivered by inhala-
tion will be given to destroy such early tumors before they
become invasive.
Because of major advances in these new technologies,
lung cancer screening programs should be reopened, per-
haps by combining the use of low-dose helical CT and
immunostaining techniques. Initially, at least, eligibility for
those programs should be restricted to very high-risk pa-
tients.
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